Home > Quotes > AEGR
AEGR

Aegerion Pharmaceuticals, Inc. Common Stock Quote & Summary Data

$2.85
*  
0.12
4.04%
Get AEGR Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading AEGR now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Aegerion Pharmaceuticals, Inc. Common Stock Intraday Chart




News for AEGR

Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 3.04 $ 25.06
Low $ 2.80 $ 2.91

The current last sale of $2.85 is -2.06% Lower thanthe 52 week low.

P/E Ratio

ETFs with AEGR as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0% BioShares Biotechnology Products Fund (BBP) -3.54 (-11.66%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Our first product, lomitapide, received marketing approval, under the brand name JUXTAPID® (lomitapide) capsules ("JUXTAPID"), from the U.S. Food and Drug Administration ("FDA") in December 2012, as an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). We launched JUXTAPID in the U.S. in January 2013.  ... More ...  

Risk Grade

Where does AEGR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?